SALA, GIANLUCA
 Distribuzione geografica
Continente #
NA - Nord America 1.775
EU - Europa 1.219
AS - Asia 721
OC - Oceania 3
AF - Africa 2
SA - Sud America 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 3.723
Nazione #
US - Stati Uniti d'America 1.772
IT - Italia 365
SG - Singapore 317
IE - Irlanda 296
CN - Cina 231
SE - Svezia 184
UA - Ucraina 85
DE - Germania 67
TR - Turchia 67
FR - Francia 56
IN - India 45
GB - Regno Unito 44
RU - Federazione Russa 39
VN - Vietnam 35
FI - Finlandia 26
BE - Belgio 18
CZ - Repubblica Ceca 9
GR - Grecia 7
NL - Olanda 6
AE - Emirati Arabi Uniti 4
CH - Svizzera 4
HK - Hong Kong 4
CA - Canada 3
IL - Israele 3
JP - Giappone 3
AU - Australia 2
BG - Bulgaria 2
LK - Sri Lanka 2
MY - Malesia 2
TW - Taiwan 2
AL - Albania 1
AR - Argentina 1
AT - Austria 1
CL - Cile 1
DK - Danimarca 1
EG - Egitto 1
ES - Italia 1
EU - Europa 1
HR - Croazia 1
HU - Ungheria 1
ID - Indonesia 1
KR - Corea 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
LT - Lituania 1
LU - Lussemburgo 1
MK - Macedonia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
RS - Serbia 1
TH - Thailandia 1
Totale 3.723
Città #
Chandler 411
Dublin 293
Singapore 277
Jacksonville 178
Princeton 114
Ashburn 92
Ann Arbor 85
Santa Clara 76
Beijing 59
Chieti 54
Altamura 52
Boardman 48
Nanjing 45
Dearborn 44
Izmir 36
Dong Ket 35
Pescara 34
Wilmington 34
Los Angeles 28
Southend 22
New York 21
Brussels 18
Washington 18
Cambridge 16
Seattle 15
Munich 14
Nanchang 13
Pune 13
Collecorvino 12
Hebei 11
Lappeenranta 10
Mcallen 10
Norwalk 10
Woodbridge 10
Milan 9
Montesilvano 8
Shenyang 8
Falls Church 7
Zhengzhou 7
Brno 6
Fairfield 6
Helsinki 6
Kunming 6
Rome 6
Tianjin 6
Finale Ligure 5
Frankfurt am Main 5
Moscow 5
Shijiazhuang 5
Dubai 4
Hong Kong 4
Houston 4
Jinan 4
Newark 4
Redwood City 4
Romola 4
Stockholm 4
Tappahannock 4
Changsha 3
Città Sant'Angelo 3
Guangzhou 3
Hefei 3
Jiaxing 3
London 3
Napoli 3
Nuremberg 3
Olomouc 3
Parma 3
Perugia 3
Tel Aviv 3
Valdagno 3
Ancona 2
Andover 2
Cattolica 2
Chicago 2
Chongqing 2
Civitanova Marche 2
Colombo 2
Cosenza 2
Dübendorf 2
Edinburgh 2
Espoo 2
Frankfurt (Oder) 2
Fuzhou 2
Grevenbroich 2
Kocaeli 2
Lanzhou 2
Leinì 2
L’Aquila 2
Messina 2
Miami 2
Montesilvano Marina 2
Ningbo 2
San Jose 2
San Salvo 2
Sansepolcro 2
Sofia 2
Spoltore 2
Taipei 2
Taizhou 2
Totale 2.436
Nome #
miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance 132
EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma 120
EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma 108
Functional and prognostic significance of the genomic amplification of frizzled 6 (FZD6) in breast cancer 105
ERBB3 BINDING ANTIBODY 97
Secreted Gal-3BP is a novel promising target for non-internalizing Antibody–Drug Conjugates 97
ErbB-3 activation by NRG-1β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs) 95
Repurposing a psychoactive drug for children with cancer: p27 Kip1-dependent inhibition of metastatic neuroblastomas by Prozac 94
Therapeutic efficacy of the novel stimuli-sensitive nano-ferritins containing doxorubicin in a head and neck cancer model 93
CAF-Derived IL6 and GM-CSF Cooperate to Induce M2-like TAMs–Letter 93
Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma 92
BAG3 promotes pancreatic ductal adenocarcinoma growth by activating stromal macrophages 89
Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer. 85
ABCC3 is a novel target for the treatment of pancreatic cancer 85
Combined effect of anti-BAG3 and anti-PD-1 treatment on macrophage infiltrate, CD8(+) T cell number and tumour growth in pancreatic cancer 84
miR-574-5p as RNA decoy for CUGBP1 stimulates human lung tumor growth by mPGES-1 induction. 84
Development of an anti-BAG3 humanized antibody for treatment of pancreatic cancer 82
PLC-gamma-1 phosphorylation status is prognostic of metastatic risk in patients with early-stage Luminal-A and -B breast cancer subtypes 82
Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer 78
GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine 72
Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer 72
The role of phospholipase Cγ1 in breast cancer and its clinical significance 71
LGALS3BP antibody-drug-conjugate and its use for the treatment of cancer 71
Humanized anti-bag3 antibodies 70
The G-protein-coupled receptor kinase GRK4 mediates homologous desensitization of metabotropic glutamate receptor 1 70
Phospholipase Cgamma1 is required for metastasis development and progression 69
HER3 targeting with an antibody-drug conjugate bypasses resistance to anti-HER2 therapies 68
The E27 β2-adrenergic receptor polymorphism reduces the risk of myocardial infarction in dyslipidemic young males 63
EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo. 62
EV20‑sss‑vc/MMAF, an HER‑3 targeting antibody‑drug conjugate displays antitumor activity in liver cancer 62
The role of phosphoinositide 3-kinase C2α in insulin signaling 58
Targeting vesicular lgals3bp by an antibody-drug conjugate as novel therapeutic strategy for neuroblastoma 58
An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling. 58
Antibody-drug conjugates: The new frontier of chemotherapy 57
Dual PDK1/aurora kinase a inhibitors reduce pancreatic cancer cell proliferation and colony formation 56
Feedback inhibition by RALT controls signal output by the ErbB network 51
Expression of RALT, a feedback inhibitor of ErbB receptors, is subjected to an integrated transcriptional and post-translational control 51
BAG3 induces fibroblasts to release key cytokines involved in pancreatic cell migration 51
HPLC-DAD validated method for DM4 and its metabolite S-Me-DM4 quantification in biological matrix for clinical and pharmaceutical applications 50
HER-3: Hub for escape mechanisms 50
Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines 50
P63 role in breast cancer 49
Breast cancer in the era of integrating "Omics" approaches 46
Negative regulation of receptor tyrosine kinase signals 45
Engineered human nanoferritin bearing the drug genz-644282 for cancer therapy 44
Endosialin-binding antibody 43
Role of BAG3 in cancer progression: A therapeutic opportunity 42
High activity and low toxicity of a novel CD71-targeting nanotherapeutic named The-0504 on preclinical models of several human aggressive tumors 42
Concerted BAG3 and SIRPα blockade impairs pancreatic tumor growth 42
Anti-LGALS3BP antibody-drug conjugate treatment induces durable and potent antitumor response in a preclinical model of adenoid cystic carcinoma 40
Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin 40
EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors 40
Extracellular LGALS3BP: a potential disease marker and actionable target for antibody-drug conjugate therapy in glioblastoma 38
Extracellular vesicles in glioblastoma: Biomarkers and therapeutic tools 38
A phosphoinositide 3-kinase/phospholipase cgamma1 pathway regulates fibroblast growth factor-induced capillary tube formation 37
HER-3 surface expression increases in advanced colorectal cancer representing a potential therapeutic target 35
MYC regulates metabolism through vesicular transfer of glycolytic kinases 35
USP19 modulates cancer cell migration and invasion and acts as a novel prognostic marker in patients with early breast cancer 34
LGALS3BP is a potential target of antibody-drug conjugates in oral squamous cell carcinoma 31
Visualizing Galectin-3 Binding Protein Expression with ImmunoPET 29
Effects of an ErbB-3 antibody, MP-RM-1, on tumor growth and ligand-dependent and -independent activation of ErbB-3/akt signaling 26
Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target 24
The mitotic checkpoint kinase BUB1 is a direct and actionable target of MYB in adenoid cystic carcinoma 22
Therapeutic potential of antibody‐drug conjugate‐based therapy in head and neck cancer: A systematic review 19
Widespread in vivo efficacy of The-0504: A conditionally-activatable nanoferritin for tumor-agnostic targeting of CD71-expressing cancers 18
Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans 17
Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer 17
EV20/Omomyc: A novel dual MYC/HER3 targeting immunoconjugate 12
Cold atmospheric plasma activated media selectively affects human head and neck cancer cell lines 10
Totale 4.050
Categoria #
all - tutte 19.566
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.566


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020384 0 0 0 0 0 32 72 24 53 127 67 9
2020/2021337 39 3 60 7 23 60 24 15 16 34 9 47
2021/2022333 15 2 5 62 18 12 13 23 29 20 28 106
2022/20231.065 94 175 71 124 92 176 49 89 129 12 38 16
2023/2024638 38 15 64 33 36 214 97 26 5 25 13 72
2024/2025786 60 301 242 66 45 72 0 0 0 0 0 0
Totale 4.050